• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环生长分化因子 15 水平升高与慢性肾脏病患者心率变异性降低有关。

Elevated circulating growth differentiation factor 15 is related to decreased heart rate variability in chronic kidney disease patients.

机构信息

Center for Kidney Disease, 2nd Affiliated Hospital, Nanjing Medical University, Nanjing, China.

Department of Radiology, University of Washington, Seattle, WA, USA.

出版信息

Ren Fail. 2021 Dec;43(1):340-346. doi: 10.1080/0886022X.2021.1880938.

DOI:10.1080/0886022X.2021.1880938
PMID:33567936
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7889148/
Abstract

BACKGROUND

Growth differentiation factor 15(GDF15) is a distant member of the superfamily of the transforming growth factor beta (TGF-β). It has been established that increased GDF15 levels are associated with an increased risk of cardiovascular disease. However, the detail effect of GDF15 on cardiovascular system in patients with chronic kidney disease (CKD) needs detail analysis.

METHODS

Patients with CKD who did not need dialysis were enrolled in the study. Blood pressure (BP), endothelial function, pulse wave velocity (PWV) and heart rate variability (HRV) were taken in all subjects. Plasma GDF15 concentration was measured by an enzyme-linked immunosorbent assay.

RESULTS

Among the 355 participants, the mean age was 57.4 (±14.2) years old and the mean estimated glomerular filtration rate (eGFR) was 50.1 (±33.2) mL/min/1.73m. The average plasma GDF15 level was 1394.7 (±610.1) pg/mL. Higher GDF15 concentrations were significantly associated with decreased eGFR and increased urine protein-to-creatinine ratio (uPCR). In multivariable models, after adjusting for potential confounders, plasma GDF15 has negative concerning with HRV parameters including the standard deviation of the normal-to-normal (NN) interval (SDNN), the square root of the mean of the sum of the squares of differences between adjacent NN intervals (RMSSD) and Triangular Index.

CONCLUSION

We observed there was a link between increased plasma of GDF15 and decreased HRV. The mechanisms and prediction of GDF15 in the cardiovascular disease with CKD needs further discussion and study.

摘要

背景

生长分化因子 15(GDF15)是转化生长因子β(TGF-β)超家族的一个远亲。已经证实,GDF15 水平的升高与心血管疾病风险的增加有关。然而,GDF15 对慢性肾脏病(CKD)患者心血管系统的详细影响需要详细分析。

方法

本研究纳入了不需要透析的 CKD 患者。所有患者均测量血压(BP)、内皮功能、脉搏波速度(PWV)和心率变异性(HRV)。通过酶联免疫吸附试验测量血浆 GDF15 浓度。

结果

在 355 名参与者中,平均年龄为 57.4(±14.2)岁,平均估算肾小球滤过率(eGFR)为 50.1(±33.2)mL/min/1.73m。平均血浆 GDF15 水平为 1394.7(±610.1)pg/mL。较高的 GDF15 浓度与较低的 eGFR 和较高的尿蛋白/肌酐比值(uPCR)显著相关。在多变量模型中,在调整了潜在混杂因素后,血浆 GDF15 与 HRV 参数呈负相关,包括正常-正常(NN)间期的标准差(SDNN)、NN 间期差值均方根(RMSSD)和三角指数。

结论

我们观察到血浆 GDF15 升高与 HRV 降低之间存在关联。GDF15 在 CKD 心血管疾病中的机制和预测需要进一步讨论和研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eb5/7889148/93e2508dd184/IRNF_A_1880938_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eb5/7889148/93e2508dd184/IRNF_A_1880938_F0001_B.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4eb5/7889148/93e2508dd184/IRNF_A_1880938_F0001_B.jpg

相似文献

1
Elevated circulating growth differentiation factor 15 is related to decreased heart rate variability in chronic kidney disease patients.循环生长分化因子 15 水平升高与慢性肾脏病患者心率变异性降低有关。
Ren Fail. 2021 Dec;43(1):340-346. doi: 10.1080/0886022X.2021.1880938.
2
Increased circulating bioactive C-type natriuretic peptide is associated with reduced heart rate variability in patients with chronic kidney disease.循环中生物活性C型利钠肽水平升高与慢性肾脏病患者心率变异性降低有关。
BMC Nephrol. 2018 Mar 5;19(1):50. doi: 10.1186/s12882-018-0843-3.
3
Associations Between Kidney Disease Measures and Regional Pulse Wave Velocity in a Large Community-Based Cohort: The Atherosclerosis Risk in Communities (ARIC) Study.在一个大型社区队列中,肾脏疾病指标与区域脉搏波速度的相关性:动脉粥样硬化风险社区(ARIC)研究。
Am J Kidney Dis. 2018 Nov;72(5):682-690. doi: 10.1053/j.ajkd.2018.04.018. Epub 2018 Jul 12.
4
GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.生长分化因子 15、半乳糖凝集素 3、可溶性 ST2 与慢性肾脏病患者的死亡率和心血管事件风险
Am J Kidney Dis. 2018 Oct;72(4):519-528. doi: 10.1053/j.ajkd.2018.03.025. Epub 2018 Jun 14.
5
Association of serum adiponectin concentration with aortic arterial stiffness in chronic kidney disease: from the KNOW-CKD study.慢性肾脏病患者血清脂联素浓度与主动脉僵硬度的关联:来自慢性肾脏病知晓研究(KNOW-CKD study)
Clin Exp Nephrol. 2017 Aug;21(4):608-616. doi: 10.1007/s10157-016-1322-4. Epub 2016 Aug 11.
6
Growth Differentiation Factor-15 and Risk of CKD Progression.生长分化因子-15与慢性肾脏病进展风险
J Am Soc Nephrol. 2017 Jul;28(7):2233-2240. doi: 10.1681/ASN.2016080919. Epub 2017 Feb 3.
7
Heart rate variability is a predictor of mortality in chronic kidney disease: a report from the CRIC Study.心率变异性是慢性肾脏病患者死亡率的预测指标:来自 CRIC 研究的报告。
Am J Nephrol. 2013;38(6):517-28. doi: 10.1159/000357200. Epub 2013 Dec 14.
8
Urinary growth differentiation factor 15 predicts renal function decline in diabetic kidney disease.尿生长分化因子 15 可预测糖尿病肾病患者肾功能下降。
Sci Rep. 2023 Aug 2;13(1):12508. doi: 10.1038/s41598-023-39657-7.
9
[Role of the morphogenetic proteins FGF-23 and Klotho and the glycoprotein sclerostin in the assessment of the risk of cardiovascular diseases and the prognosis of chronic kidney disease].[形态发生蛋白FGF-23和Klotho以及糖蛋白硬化蛋白在评估心血管疾病风险和慢性肾脏病预后中的作用]
Ter Arkh. 2015;87(6):10-16. doi: 10.17116/terarkh201587610-16.
10
Cardiac and Stress Biomarkers and Chronic Kidney Disease Progression: The CRIC Study.心脏和应激生物标志物与慢性肾脏病进展:CRIC 研究。
Clin Chem. 2019 Nov;65(11):1448-1457. doi: 10.1373/clinchem.2019.305797. Epub 2019 Oct 2.

引用本文的文献

1
Health implications of racial differences in serum growth differentiation factor levels among men with obesity.肥胖男性血清生长分化因子水平种族差异对健康的影响
Physiol Rep. 2024 Dec;12(23):e70124. doi: 10.14814/phy2.70124.
2
Association Between Circulating GDF-15 and Cardio-Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial.循环 GDF-15 与心肾结局的关系及坎格列净的作用:来自 CANVAS 试验的结果。
J Am Heart Assoc. 2021 Dec 7;10(23):e021661. doi: 10.1161/JAHA.121.021661. Epub 2021 Dec 2.
3
Negative Regulators of Inflammation Response to the Dynamic Expression of Cytokines in DF-1 and MDCK Cells Infected by Avian Influenza Viruses.

本文引用的文献

1
Cardiac and Stress Biomarkers and Chronic Kidney Disease Progression: The CRIC Study.心脏和应激生物标志物与慢性肾脏病进展:CRIC 研究。
Clin Chem. 2019 Nov;65(11):1448-1457. doi: 10.1373/clinchem.2019.305797. Epub 2019 Oct 2.
2
Growth differentiation factor 15 is decreased by kidney transplantation.生长分化因子 15 在肾移植后减少。
Clin Biochem. 2019 Nov;73:57-61. doi: 10.1016/j.clinbiochem.2019.07.013. Epub 2019 Jul 27.
3
Growth differentiation factor 15 (GDF15): A survival protein with therapeutic potential in metabolic diseases.
炎症反应负调控因子对感染禽流感病毒的 DF-1 和 MDCK 细胞中细胞因子动态表达的影响。
Inflammation. 2022 Apr;45(2):573-589. doi: 10.1007/s10753-021-01568-y. Epub 2021 Sep 28.
生长分化因子 15(GDF15):一种代谢疾病治疗潜力的生存蛋白。
Pharmacol Ther. 2019 Jun;198:46-58. doi: 10.1016/j.pharmthera.2019.02.008. Epub 2019 Feb 18.
4
GDF15 and Growth Control.生长分化因子15与生长调控
Front Physiol. 2018 Nov 27;9:1712. doi: 10.3389/fphys.2018.01712. eCollection 2018.
5
The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases.MIC-1/GDF15-GFRAL 通路与能量稳态:肥胖症、恶病质及其他相关疾病的影响。
Cell Metab. 2018 Sep 4;28(3):353-368. doi: 10.1016/j.cmet.2018.07.018.
6
GDF-15, Galectin 3, Soluble ST2, and Risk of Mortality and Cardiovascular Events in CKD.生长分化因子 15、半乳糖凝集素 3、可溶性 ST2 与慢性肾脏病患者的死亡率和心血管事件风险
Am J Kidney Dis. 2018 Oct;72(4):519-528. doi: 10.1053/j.ajkd.2018.03.025. Epub 2018 Jun 14.
7
Increased circulating bioactive C-type natriuretic peptide is associated with reduced heart rate variability in patients with chronic kidney disease.循环中生物活性C型利钠肽水平升高与慢性肾脏病患者心率变异性降低有关。
BMC Nephrol. 2018 Mar 5;19(1):50. doi: 10.1186/s12882-018-0843-3.
8
Targeting Obesity and Cachexia: Identification of the GFRAL Receptor-MIC-1/GDF15 Pathway.靶向肥胖与恶病质:GFRAL 受体-MIC-1/GDF15 通路的鉴定。
Trends Mol Med. 2017 Dec;23(12):1065-1067. doi: 10.1016/j.molmed.2017.10.005. Epub 2017 Nov 9.
9
Heart rate variability and lifetime risk of cardiovascular disease: the Atherosclerosis Risk in Communities Study.心率变异性与心血管疾病的终生风险:社区动脉粥样硬化风险研究
Ann Epidemiol. 2017 Oct;27(10):619-625.e2. doi: 10.1016/j.annepidem.2017.08.024. Epub 2017 Oct 3.
10
GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand.GFRAL 是 GDF15 的受体,是配体发挥抗肥胖作用所必需的。
Nat Med. 2017 Oct;23(10):1158-1166. doi: 10.1038/nm.4394. Epub 2017 Aug 28.